A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease

Next Previous
Trial Profile

A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Cardiovascular disorders; Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia; Myocardial infarction; Stroke
  • Focus Adverse reactions
  • Sponsors Amgen

    • Most Recent Events

    • 09 Jun 2017 Planned End Date changed from 1 Oct 2021 to 29 Sep 2021.
    • 09 Jun 2017 Planned primary completion date changed from 1 Oct 2021 to 29 Sep 2021.
    • 12 Dec 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top